Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Buy
62
ALGS Quote, Financials, Valuation and Earnings
Last price:
$43.51
Seasonality move
:
7.18%
Day range:
$38.90 - $42.42
52-week range:
$6.76 - $42.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
35.73x
P/B ratio:
2.82x
Volume:
290.4K
Avg. volume:
537.8K
1-year change:
124.8%
Market cap:
$141.1M
Revenue:
$15.5M
EPS (TTM):
-$17.11
Analysts' Opinion
-
Consensus RatingAligos Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $108.33, Aligos Therapeutics has an estimated upside of 162.67% from its current price of $39.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $75.00 representing 100% downside risk from its current price of $39.34.
Fair Value
-
According to the consensus of 1 analyst, Aligos Therapeutics has 162.67% upside to fair value with a price target of $108.33 per share.
ALGS vs. S&P 500
-
Over the past 5 trading days, Aligos Therapeutics has overperformed the S&P 500 by 10.86% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Aligos Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aligos Therapeutics revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Aligos Therapeutics reported revenues of $1.3M.
Earnings Growth
-
Aligos Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Aligos Therapeutics reported earnings per share of -$3.07.
Enterprise value:
66.2M
EV / Invested capital:
1.32x
Price / LTM sales:
35.73x
EV / EBIT:
--
EV / Revenue:
11.04x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.78x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-68.4%
Net Income Margin (TTM):
-1283.19%
Return On Equity:
-118.75%
Return On Invested Capital:
-118.75%
Operating Margin:
-1586.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $10.7M | $16.4M | $6M | $3.2M | $1.3M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$112.8M | -$84.8M | -$94.6M | -$19.1M | -$20.1M | |
| EBITDA | -$109.1M | -$81.6M | -$91.9M | -$18.4M | -$19.5M | |
| Diluted EPS | -$66.00 | -$47.12 | -$17.11 | -$10.37 | -$3.07 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $73.7M | $248.7M | $150.1M | $74.6M | $79.8M | |
| Total Assets | $92.2M | $263.1M | $164.1M | $85.9M | $88.4M | |
| Current Liabilities | $20M | $34.8M | $30.5M | $22.5M | $21M | |
| Total Liabilities | $228.9M | $46.1M | $42.1M | $31M | $38.3M | |
| Total Equity | -$136.7M | $217M | $122M | $54.8M | $50.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$100.1M | -$73.1M | -$85M | -$20.3M | -$20.1M | |
| Cash From Investing | -$54.4M | $56.6M | -$38.3M | -$9K | $10.4M | |
| Cash From Financing | $595K | $513K | $88.2M | -$21K | -$4K | |
| Free Cash Flow | -$101.3M | -$73.2M | -$85.1M | -$20.3M | -$20.1M | |
ALGS
Sector
Market Cap
$141.1M
$46.1M
Price % of 52-Week High
91.6%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
124.8%
-30.52%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$36.44
200-day SMA
Buy
Level
$16.40
Bollinger Bands (100)
Buy
Level
6.92 - 24.5
Chaikin Money Flow
Sell
Level
-16.3M
20-day SMA
Buy
Level
$31.12
Relative Strength Index (RSI14)
Buy
Level
77.53
ADX Line
Buy
Level
25.65
Williams %R
Neutral
Level
-20.4983
50-day SMA
Buy
Level
$19.88
MACD (12, 26)
Buy
Level
5.44
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
11.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.8832)
Sell
CA Score
(Annual)
Level (-2.3677)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.7222)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Stock Forecast FAQ
In the current month, ALGS has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ALGS average analyst price target in the past 3 months is $108.33.
-
Where Will Aligos Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aligos Therapeutics share price will rise to $108.33 per share over the next 12 months.
-
What Do Analysts Say About Aligos Therapeutics?
Analysts are divided on their view about Aligos Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aligos Therapeutics is a Sell and believe this share price will drop from its current level to $75.00.
-
What Is Aligos Therapeutics's Price Target?
The price target for Aligos Therapeutics over the next 1-year time period is forecast to be $108.33 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ALGS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aligos Therapeutics is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ALGS?
You can purchase shares of Aligos Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aligos Therapeutics shares.
-
What Is The Aligos Therapeutics Share Price Today?
Aligos Therapeutics was last trading at $43.51 per share. This represents the most recent stock quote for Aligos Therapeutics. Yesterday, Aligos Therapeutics closed at $39.34 per share.
-
How To Buy Aligos Therapeutics Stock Online?
In order to purchase Aligos Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 2.02% over the past day.
